Market Overview - The Shanghai Composite Index is at 3852.31 points with a decline of -0.21% as of 10:32 AM, and the total trading volume of A-shares is 1,075.764 billion yuan [1] Stocks with Death Cross - A total of 152 A-shares have seen their 5-day moving average cross below the 10-day moving average, indicating potential bearish trends [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Songjing Co., Ltd. (688157) with a distance of -1.61% - Chunguang Technology (603657) with a distance of -1.02% - Pilin Bio (000403) with a distance of -0.93% [1] Detailed Stock Performance - Key stock performances include: - Songjing Co., Ltd. (688157): Today's change is -0.67% with a latest price of 40.09 yuan, which is -3.28% from the 10-day moving average [1] - Chunguang Technology (603657): Today's change is -3.47% with a latest price of 38.70 yuan, which is -6.79% from the 10-day moving average [1] - Pilin Bio (000403): Today's change is -0.52% with a latest price of 17.32 yuan, which is -2.64% from the 10-day moving average [1] Additional Stocks with Notable Changes - Other stocks showing significant changes include: - Jiangsu New Energy (603693): Today's change is -1.38% with a latest price of 12.87 yuan, which is -2.29% from the 10-day moving average [2] - Yongan Pharmaceutical (002365): Today's change is -1.04% with a latest price of 18.11 yuan, which is -1.45% from the 10-day moving average [2] - Mosi Co., Ltd. (001323): Today's change is -1.95% with a latest price of 28.16 yuan, which is -2.96% from the 10-day moving average [2]

Group 1 - The core point of the announcement is that the controlling shareholder, Huanggang Yong'an Pharmaceutical Co., Ltd., plans to reduce its shareholding in the company by up to 2,632,300 shares, which is approximately 0.8933% of the total share capital [1] - As of September 4, 2025, Huanggang Yong'an has already reduced its holdings by 410,000 shares, representing 0.1391% of the total share capital, bringing the total shares held by the controlling shareholder and its concerted actors to 73,587,232 shares, or 24.9717% of the total share capital [2] Group 2 - The company has approved the use of up to RMB 750 million of its own funds for entrusted wealth management, with a validity period of no more than 12 months [3] - On September 5, 2025, the wholly-owned subsidiary, Wuhan Yaan Investment Management Co., Ltd., invested RMB 16 million in a wealth management product from Guotai Haitong Securities, with an expected annualized return of 3.5% plus excess returns [4][5] - The company has also made several other investments in wealth management products, including a RMB 34 million investment in a product from China Zhongjin Wealth Securities with an expected return of 2.5%-3.5% [6][7] - As of the announcement date, the total amount of wealth management products purchased using idle funds is approximately RMB 61,240 million, accounting for 30.72% of the most recent audited net assets [24]

Group 1 - The controlling shareholder's action, Huanggang Yong'an, reduced its stake by 410,000 shares on September 4, 2025, accounting for 0.1391% of the total share capital [1] - After this equity change, the total shares held by the controlling shareholder, actual controller, and their concerted parties amount to 73.5872 million shares, representing 24.9717% of the total [1] - The shareholding percentage has reached a multiple of 5% [1]

潜江永安药业股份有限公司 简式权益变动报告书 上市公司名称：潜江永安药业股份有限公司 股票上市地点：深圳证券交易所 股票简称：永安药业 股票代码：002365 信息披露义务人1：陈勇 住所：湖北省武汉市*** 通讯地址：湖北省潜江市经济开发区广泽大道2号 权益变动性质：持股不变 信息披露义务人2：黄冈永安药业有限公司 住所/通讯地址：团风县城南工业园 权益变动性质：持股比例减少 签署日期：2025年9月8日 信息披露义务人声明 一、本报告书系信息披露义务人依据《中华人民共和国公司法》《中华人 民 共和国证券法》《上市公司收购管理办法》《公开发行证券公司信息披露内容 与格 式准则第 15 号——权益变动报告书》及其他相关法律、法规和规范性文件 编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》等规定， 本报告书已全面披露信息披露义务人在潜江永安药业股份有限公司中拥有权 益的股份变动情况；截至本报告书签署之日，除本报告书披露的信息外，上述 信息披露义务人没有通过任何其他方式增加或减少其在潜江永安药业股份有 限公司拥有权益的股份。 四、本次权益变 ...

证券代码：002365 证券简称：永安药业 公告编号：2025-51 潜江永安药业股份有限公司（以下简称"公司"）于 2025 年 7 月 25 日披露 了《关于公司控股股东、实际控制人之一致行动人拟减持公司股份的预披露公告》 （公告编号：2025-45），公司控股股东、实际控制人之一致行动人黄冈永安药 业有限公司（以下简称"黄冈永安"）持有公司股份 10,529,232 股（占总股 本比例 3.5731%，占剔除公司回购专用账户股份后的总股本比例 3.6415%）计划自 本公告披露之日起十五个交易日后的三个月内以集中竞价交易或大宗交易方式减 持公司股份不超过 2,632,300 股（占总股本比例 0.8933%，占剔除公司回购专用账 户股份后的总股本比例 0.9104%）。 潜江永安药业股份有限公司 关于控股股东、实际控制人及其一致行动人权益变动 触及 5%整数倍的提示性公告 本公司控股股东、实际控制人及其一致行动人保证向本公司提供的信息内容 真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 4．承诺、计划等履行情况 | | 是☑ 否 ...

证券代码：002365 证券简称：永安药业 公告编号：2025-52 潜江永安药业股份有限公司 关于购买理财产品的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 潜江永安药业股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日、2025 年 6 月 24 日分别召开了第七届董事会第六次临时会议及 2024 年年度股东会，审 议通过了《关于使用自有资金进行委托理财的议案》，同意公司及子公司总计使 用最高额度不超过（含）人民币 7.5 亿元的自有资金进行委托理财。上述额度 可滚动使用，有效期自股东会审议通过之日起不超过 12 个月，并授权公司管理 层具体实施相关事宜。公司根据上述决议，择机购买了相关理财产品，现将有关 情况公告如下： 一、理财产品的主要情况 （一）2025 年 9 月 5 日，全资子公司武汉雅安投资管理有限公司（以下简 称"雅安投资"）出资 1600 万元，向国泰海通证券股份有限公司（以下简称"国 泰海通"）购买理财产品，具体情况如下： 1、产品名称：国泰海通私客尊享 F0F7063 号单一资产管理计划 2、产品代码：955 ...

Core Viewpoint - The announcement from Yong'an Pharmaceutical indicates that the actual controller and chairman, Chen Yong, has had his detention measures lifted, allowing him to resume normal duties, which is expected to stabilize the company's management [2][4]. Group 1: Company Background - Yong'an Pharmaceutical is a leading enterprise in the taurine industry, primarily engaged in the research, production, and sales of taurine products, health foods, and special dietary foods [6]. - The company holds approximately 50% of the global market share in taurine production, with an annual production capacity of 58,000 tons, making it a key supplier for major global brands like Red Bull, Nestlé, and Coca-Cola [6]. Group 2: Financial Performance - The company's financial performance has shown a downward trend, with revenues decreasing from 1.462 billion yuan in 2022 to 839 million yuan in 2024, and net profits declining from 133 million yuan to a loss of 28.41 million yuan during the same period [7]. - In the first half of the current year, Yong'an Pharmaceutical reported revenues of 367 million yuan, a year-on-year decline of 13.7%, and a net profit of 8.55 million yuan, down 83% compared to the previous year [7]. Group 3: New Business Prospects - The company is focusing on the development of creatine products, which are still in the early stages and unlikely to significantly boost performance in the short term [9]. - Yong'an's subsidiary, Ling'an Technology, is undergoing a business transformation to develop monohydrate creatine, leveraging existing production and sales channels to enhance growth potential [9]. - Investors are particularly interested in whether Chen Yong's return will help the company overcome its performance challenges and if the new business initiatives can serve as a growth engine [9].

Group 1 - The graphite electrode sector saw a rise of 5.26%, ranking 8th among concept sectors, with 23 stocks increasing in value, including Shangtai Technology and Putailai hitting the daily limit [1] - Notable gainers in the sector included Beiterui, Daoshi Technology, and Yicheng New Energy, which rose by 19.03%, 10.29%, and 9.09% respectively [1] - The sector experienced a net inflow of 9.62 billion yuan from main funds, with 17 stocks receiving net inflows, and 8 stocks exceeding 50 million yuan in net inflow [2] Group 2 - Shangtai Technology led the net inflow with 1.98 billion yuan, followed by Putailai, Shanshan Co., and Suotong Development with net inflows of 1.77 billion yuan, 1.56 billion yuan, and 861.67 million yuan respectively [2] - The top stocks by net inflow ratio included Shangtai Technology, Longjiang Transportation, and Yunmei Energy, with ratios of 19.19%, 11.45%, and 11.11% respectively [3] - The trading performance of key stocks in the graphite electrode sector showed significant activity, with Shangtai Technology and Putailai both achieving notable price increases and trading volumes [4]

Core Viewpoint - Yong'an Pharmaceutical has resumed normal operations after the chairman's detention was lifted, despite previous management turmoil and a significant increase in stock price driven by rising taurine prices [1][2]. Company Overview - Yong'an Pharmaceutical, headquartered in Qianjiang, Hubei, specializes in taurine production, holding approximately 50% of the global market share with an annual production capacity of 58,000 tons [1]. - The company is a key supplier for major brands such as Red Bull, Nestlé, and Coca-Cola [1]. Management Changes - Chairman Chen Yong was previously detained for investigation by the Hekou County Supervisory Committee, with his son Chen Zidi temporarily taking over his responsibilities [1]. - Following the announcement of Chen Yong's detention, the company's stock price surged from 11.52 yuan on May 6 to 30.5 yuan by July 7 [1]. Market Dynamics - The increase in stock price is attributed to a rise in taurine prices, influenced by new FDA regulations requiring taurine in infant formula and pet food [2]. - Taurine prices rose from 14,250 yuan per ton in early April to as high as 25,000 yuan per ton by late April [2]. Production Expansion Plans - Despite the favorable market conditions, Yong'an Pharmaceutical has slowed down the construction of a previously approved 40,000-ton taurine production project, opting for phased development due to recent price declines [3]. - The company plans to complete the first phase of the project, which has already achieved production capacity, while the second phase will focus on additional facility upgrades [3]. Shareholder Actions - On July 24, amid ongoing uncertainties regarding the chairman's situation, the controlling shareholder, Huanggang Yong'an, announced a plan to reduce its stake in the company [4]. - Huanggang Yong'an holds 10,529,232 shares, representing 3.64% of the total share capital, and plans to sell up to 2,632,300 shares, or 0.91% of the total share capital [4].

Core Viewpoint - The return of Chen Yong, the actual controller and chairman of Yong'an Pharmaceutical, is expected to stabilize the company's management and potentially improve its performance amid ongoing challenges in the taurine market and new business development opportunities [1][6]. Group 1: Management Changes - Chen Yong has resumed his duties after the lifting of the detention measures, allowing him to manage the company normally [1]. - The transition of responsibilities to Chen Zidi has been completed, ensuring continuity in leadership during Chen Yong's absence [1][2]. Group 2: Financial Performance - Yong'an Pharmaceutical has experienced a decline in revenue for three consecutive years, with revenues of 1.462 billion, 973 million, and 839 million yuan from 2022 to 2024, representing year-on-year decreases of 6.58%, 33.48%, and 13.78% respectively [3]. - The core business of taurine generated 635 million yuan in revenue in 2024, accounting for 75.67% of total revenue, but saw a year-on-year decline of 4.14% despite a 16.32% increase in sales volume due to falling prices [3]. Group 3: Operational Challenges - The company's epoxy ethane and Qian'an hydrogen energy facilities were largely idle, resulting in a loss of 17.588 million yuan, which constituted 28.47% of net profit attributable to shareholders [4]. - The production of taurine has been impacted by increased costs due to the need to purchase raw materials, further squeezing profit margins [4]. Group 4: New Business Development - Yong'an Pharmaceutical has initiated a new business line in creatine, which is still in its early stages and unlikely to significantly boost performance in the short term [5]. - The subsidiary Ling'an Technology reported a revenue of 45.7128 million yuan in the first half of the year, a 53.93% increase year-on-year, but also faced a net loss of 6.6258 million yuan, indicating challenges in scaling the new product line [5][6].